Navigation Links
Drug a New Treatment Option for Diabetic Eye Disease
Date:4/28/2010

Lucentis is first new therapy against diabetic macular edema in a quarter-century, experts say

WEDNESDAY, April 28 (HealthDay News) -- A new drug may be the first new treatment in 25 years for a common diabetes-linked eye condition called diabetic macular edema (DME), researchers report.

Lucentis (ranibizumab) was originally developed to treat age-related macular degeneration. But researchers say it can also improve vision in people with DME, a common form of diabetic retinopathy.

The study of 691 patients with DME found that 50 percent of those who received Lucentis eye injections, plus laser treatment if necessary, had substantial improvement in vision one year after treatment, compared with 28 percent of patients who received laser treatment alone. Results were similar after two years.

For 25 years, laser treatment has been the standard of care for DME, the main cause of vision loss in people with diabetes.

The study, published online in the journal Ophthalmology, was conducted by the Diabetic Retinopathy Clinical Research (DRCR) Network.

According to the U.S. National Eye Institute, DME occurs when fluid leaks into the center of the macula, the portion of the eye dedicated to sharp, straight-ahead vision. The condition is common in people with diabetic retinopathy, which affects up to 45 percent of people with diabetes.

The results of the new study "appear to be applicable to most people who have DME in the center of the macula with some vision loss, whether the person has type 1 or type 2 diabetes, is old or young, or is a woman or a man," Dr. Neil M. Bressler, chair of the DRCR Network and chief of the retina division, Wilmer Eye Institute, at Johns Hopkins University School of Medicine, said in a news release.

This is a "seminal" study," added Dr. George A. Williams, a board member of the American Academy of Ophthalmology and chair of the ophthalmology department at Oakland University William Beaumont School of Medicine.

"First and most importantly, it provides patients an improved therapy for diabetic macular edema. Second, the DRCR Network study is the first multi-center, randomized clinical trial to show how ranibizumab and the laser work together to improve treatment," Williams said.

The American Academy of Ophthalmology will review the study findings and make recommendations on whether Lucentis plus laser treatment should be the preferred treatment for a large number of patients with DME.

More information

The American Diabetes Association has more about diabetes-related eye complications.



-- Robert Preidt



SOURCE: American Academy of Ophthalmology, news release, April 27, 2010


'/>"/>
Copyright©2010 ScoutNews,LLC.
All rights reserved

Related medicine news :

1. CBDM.T, The Market and Business Intelligence Company Reviews The Dry Eye Disease Treatment Market
2. Study examines global availability of treatment involving transplantation of blood stem cells
3. Study finds that drugs used for treatment of influenza in pregnancy appear to be safe
4. Comparative-effectiveness study confirms new treatment for diabetic macular edema
5. Allergy Treatment from Absolute Health Provides Allergy Elimination as Opposed to Allergy Prevention
6. CureTogether Announces Online Autism Treatment Study
7. Nonmedical treatment may rapidly relieve severe IBS symptoms
8. New Varicose Vein Treatment Center Opens in Prescott, Arizona
9. Non-medical treatment may rapidly relieve severe IBS symptoms
10. Immune cells predict success of head and neck cancer treatment, U-M study finds
11. New report confirms fears of people living with HIV: Treatment rationing escalating
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/7/2016)... ... December 07, 2016 , ... In the early morning ... to an emergency medical call when he lost control of his patrol car. The ... from his vehicle, he was transported to Atlanta Medical Center, where he later succumbed ...
(Date:12/7/2016)... ... ... They are musicians and librarians, fashion designers and fitness instructors, actors, athletes ... and around the nation. What do they have in common? All have been affected ... compelling new photographic exhibit debuting Friday, December 9 at Logan International Airport in Boston. ...
(Date:12/7/2016)... ... December 07, 2016 , ... Augustine Insurance ... to families and business owners in the greater Dallas metropolitan area, is announcing ... Fallen Officer Foundation. , Established in 2009 by active police professionals in the ...
(Date:12/7/2016)... (PRWEB) , ... December 07, 2016 , ... Sharon Kleyne, ... Global Climate Change and Your Health on Voice of America, declared on her radio ... call attention to the fact that when these bullies attack leaders in corporate America, ...
(Date:12/7/2016)... ... December 07, 2016 , ... 1105 ... Winner in the Folio: Marketing Awards competition. Live From won in the Use ... pioneering, inventive, and ultimately successful projects undertaken by the media industry’s most innovative ...
Breaking Medicine News(10 mins):
(Date:12/7/2016)... -- KEY FINDINGS Patient warming and ... loss of blood during surgeries, lowering the risks ... after surgeries, and decreasing risks of SSIs. The ... warming system, surface warming systems, and intravascular warming ... at hospitals thus, lowering the healthcare costs by ...
(Date:12/7/2016)... 7, 2016 Research and Markets has announced ... User - Global Forecast to 2021" report to their offering. ... , , ... by 2021, growing at a CAGR of 7.3% during the forecast period ... prevalence of cancer and rapidly increasing geriatric population across the globe are ...
(Date:12/7/2016)... Dec. 7, 2016 DelveInsight,s, "Janus ... provides in depth insights on the pipeline ... Janus Kinase 3 (JAK3) Inhibitors. The DelveInsight,s ... stages of development including Discovery, Pre-clinical, IND, ... Preregistration. Report covers the product clinical trials ...
Breaking Medicine Technology: